The "Pharmaceutical Speed Reader" collection is intended to incorporate the sale of SYK inhibitor assets by Gilead in Biologics.

July 17, 2020 / Medical Information List: National collection and preparation of biological products and traditional Chinese medicines, PGT-A kits as a Class III medical device for the first time into the national mandatory pharmaceutical industry standards, Gilead sold SYK inhibitor stakes, benchmark medical and Johnson Lung Cancer Center to carry out early diagnosis of lung cancer research cooperation ... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Brief The State Medical Insurance Administration held a symposium on the centralized procurement of biological products and traditional Chinese medicine on July 15-16, the relevant department of the State Medical Security Administration held a symposium to listen to expert opinions and suggestions on the centralized procurement of biological products (including insulin) and Traditional Chinese medicine, to study and improve procurement policies in related fields, and to promote the reform of procurement methods.
(National Health Insurance Administration) Health and Health Commission issued a letter: prohibit the volume of procurement monopoly 15, Shanghai Health and Health Commission, the Chinese Medicine Administration issued the "Shanghai Key Action Plan for Deepening Medical Reform (2020-2022)," the document mentioned to the management of consumables, centralized procurement and other aspects of planning, encourage and standardize third parties to participate in centralized procurement, prevent monopoly, form a fair competition industry norms, the products will not be included in the procurement.
(Shanghai Health and Health Commission, Chinese Medicine Administration) PGT-A kit as a Class III medical device for the first time into the national mandatory pharmaceutical industry standards recently, the State Drug Administration issued a statement that will further unify the understanding of mandatory industry standards, and effectively promote the mandatory industry standards for medical devices norms, effective implementation.
mentioned that THE PGT-A kit belongs to Class III medical devices, in accordance with the mandatory provisions of the relevant laws on national medical devices, any medical institutions in the implementation of clinical application projects, should use a registered medical device, product development platform must also obtain three types of medical device registration certificate.
(National Drug Administration) CDE publicly solicited the "Technical Guidelines for Joint Clinical Trials of Anti-Oncology Drugs" anti-tumor drugs is one of the current global research and development of new drugs.
in order to encourage innovation and guide the development of scientific and orderly clinical trials of anti-tumor drug combination therapy, CDE has prepared the Technical Guidelines for Clinical Trials of Anti-Tumor Drug Joint Treatment (Draft for Comments).
(CDE) Health and Health Commission issued a letter: Rural General Health Registration System has changed Hebei Province Health and Health Commission issued on the 16th "on the rural general practice assistant physician on the registration of matters of supplementary notice", proposed that the rural general practice assistant physician qualification personnel should in principle be registered in its probationary institutions;
(Hebei Province Health and Health Commission) Part 2 production and observation of Gilead's sale of SYK inhibitor assets recently, Bischofberger and the old owner reached an agreement to buy Gilead's spleen tyrosine kinase (SYK) inhibitor portfolio.
the size of the advance payment for the acquisition is unknown, Kronos Bio gave Gilead a bill that could be converted into shares and promised to pay milestone payments and associated royalties for the deal.
(Sina Pharmaceutical News) Meirui's latest results announced on the 15th, Meirui Medical released the 2020 half-year results forecast shows: in the first half of 2020, Meirui Medical achieved revenue of about 9.85 billion yuan - 10.67 billion yuan, compared with 8.2 billion yuan in the same period last year, an increase of 20%-30%;
(Seiber Blue Instruments) Zeyu Bio appointed Zhang Zhuli as Deputy General Manager of the 16th, Ze-Yu Bio issued a notice that the board of directors of the company considered and adopted the "Proposal on the appointment of senior managers of the company", agreed to appoint MR. JUNLI ZHANG (Zhang Zhuli) as the company's deputy general manager.
(Sina Pharmaceutical News) Aoxiang Pharmaceuticals appointed senior managerZhe Aoxiang Pharmaceuticals issued a notice on the appointment of senior managers, the company's second board of directors at the 18th meeting to consider and approve the "on the appointment of senior managers of the company", agreed to appoint Ms. Zhong Yu as the company's deputy general manager, Mr. Li Zhenyu as the company's board of directors secretary and finance director, the term of office from the date of the current board of directors of the company until the end of the current term of office of the board of directors.
(Sina Pharmaceutical News) Wuhan Ruijian Pharmaceuticals received tens of millions of yuan in Pre-A round financing Wuhan Ruijian Pharmaceuticals announced the completion of tens of millions of yuan of Pre-A round financing.
this round of financing by the People's Fu Industrial Fund and China Capital co-investment, will be used to complete the first Parkinson's disease research pipeline in The Health Medicine - NouvNeu001 safety evaluation and IND declaration work.
(Pharmaceutical Mission) cancer precision therapy company Relay landed on Nasdaq this week, And Therapeutics officially landed on Nasdaq, code-named RLAY.
relay issued 20 million shares($20 per share) in the IPO, bringing it to $400m.
Oncorus ONCR-177 and Mercado Oncorus, in collaboration with Mercado Keytruda, announced a clinical trial cooperation agreement with Mercadon to evaluate the efficacy of Oncorus's viral immunotherapy, ONCR-177, in conjunction with the anti-PD-1 therapy Keytruda, to treat patients with advanced and/or refractive skin, subcutaneous lymphocytic lymphoma.
(Pharmaceutical Mingkang) Benchmark Medical And Johnson Lung Cancer Center to conduct early diagnosis of lung cancer Research Today, Guangzhou Benchmark Medical and Johnson Lung Cancer Center announced a multi-year partnership in the field of early diagnosis of lung cancer to promote early lung cancer detection and diagnosis research.
this partnership was facilitated by Johnson and Johnson Innovation.
(Pharmaceutical Mingcon) Baiotai authorized Pharmapark to commercialize its Golimu monoanti-biosimilar drug Baiota in Russia and other countries announced an exclusive license agreement with Pharmapark, authorizing Pharmapark to exclusively commercialize its Golley monitaantizumab biosimilar drug BAT2506 in Russia and other CIS countries.
expects to launch the International Multicenter Phase 3 clinical trial of BAT2506 in the fourth quarter of this year, and submit a listing application to the National Drug Administration, the European EMA and the FDA after completing Phase 3 clinical trials.
(Pharmaceutical Mission) Part 3 Drug Information Therapy Alzheimer's Anti-Tau Vaccine Launch Phase 1b/2a Trial, Switzerland-based clinical phase AC Immune SA announced that it will launch its Alzheimer's vaccine ACI-35.030 higher dose group of 1b/2a clinical trials.
anti-Tau vaccine has become an important treatment strategy for AD and other neurodegenerative diseases characterized by Tau.
(Sina Pharmaceutical News) Bayer/Mersadon Heart Failure New Drug Listing Application by FDA Priority Review Bayer and Mercado jointly announced on the 16th that the U.S. FDA has accepted the new drug application for vericiguat and granted it priority review eligibility for treatment of patients with chronic heart failure with a blood score of less than 45% after experiencing worsening heart failure.
(Drug Mingcond) The world's first new drug for the world's first new drug obtained fda fast review channel qualification Soyuan Bio announced that the U.S. FDA awarded its world-first new drug DB102 for the first-line treatment of glioblastoma fast review channel qualification.
access to the fast-review channel is conditional on the absence of effective drugs, new drugs to fill treatment gaps, or new drugs with significant advantages in terms of effectiveness or safety.
(Pharmaceutical Rubik's Cube) Jingxin Pharmaceuticals "Hydrochloric Acid Kaure vellon tablets" by the United States ANDA approval number 16, Jingxin Pharmaceuticals to the FDA declared the hydrochloric acid kaerautabletapplication for a simplified new drug (ANDA) has been approved.
determined that the application for listing of the hydrochloric acid koala viron tablets and the original research Daiichi Sankyo has been listed hydrochloric acid koala tablets equivalent.
(Insight Database) Seven new drugs approved clinically from AstraZeneca, Bayer... According to the CDE website, a number of drugs are implicitly licensed for clinical trials, including PARP inhibitors, next-generation sGC agonists, OX40 monoab, CD47 antibodies, CFTR regulators, and more.
these products come from AstraZeneca, Bayer, Reding Pharmaceuticals, Hengrui Pharmaceuticals, Novartis and Vese.
(CDE) 3 class 1 new drugs approved clinically from HengRui, Reding... On the 16th, Novartis QBW251, Reding ZL-1201 injection seision and Hengrui injection SHR-1806 were approved for clinical use for bronchodilating, advanced solid tumors or malignant blood tumors and advanced malignant tumors.
(Pharmaceutical Rubik's Cube) Base Egg Biological's two products to obtain medical device registration certificate base egg biological announcement that the company's holding subsidiary Changchun Blazer recently received by jilin Provincial Drug Administration issued two "medical device registration certificate" (fully automatic urine analyzer, automatic biochemical analyzer).
as of June 30, 2020, the cumulative research and development investment of fully automatic urine analyzer has occurred about 1.8 million yuan, and the cumulative research and development investment of automatic biochemical analyzer has occurred is about 2.7 million yuan.
(base egg biological announcement) the first medical device production license issued recently, Fujian Provincial Drug Administration for Beleson Electronics issued the first medical device registration system after the pilot, Xiamen Nalong Technology holds a registration certificate, Belleson Electronics commissioned to produce digital electrocardiogram machine, thus becoming Fujian Province's first medical device registrant system pilot products.
(Cyber Blue)